Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 11, 2022

SELL
$61.48 - $73.72 $5.89 Million - $7.07 Million
-95,857 Closed
0 $0
Q4 2021

Jan 20, 2022

SELL
$53.63 - $62.52 $254,742 - $296,970
-4,750 Reduced 4.72%
95,857 $5.98 Million
Q3 2021

Oct 14, 2021

SELL
$59.17 - $69.31 $240,230 - $281,398
-4,060 Reduced 3.88%
100,607 $5.95 Million
Q2 2021

Jul 09, 2021

SELL
$61.91 - $67.42 $105,247 - $114,614
-1,700 Reduced 1.6%
104,667 $6.99 Million
Q1 2021

Apr 06, 2021

SELL
$59.34 - $66.74 $54,236 - $61,000
-914 Reduced 0.85%
106,367 $6.72 Million
Q4 2020

Jan 13, 2021

BUY
$57.74 - $65.43 $7,044 - $7,982
122 Added 0.11%
107,281 $7.02 Million
Q3 2020

Oct 01, 2020

BUY
$57.43 - $63.64 $3.48 Million - $3.85 Million
60,550 Added 129.91%
107,159 $6.46 Million
Q2 2020

Jul 08, 2020

BUY
$54.82 - $64.09 $210,508 - $246,105
3,840 Added 8.98%
46,609 $2.74 Million
Q1 2020

Apr 10, 2020

SELL
$46.4 - $67.43 $99,296 - $144,300
-2,140 Reduced 4.77%
42,769 $2.38 Million
Q4 2019

Jan 09, 2020

SELL
$49.21 - $64.19 $31,986 - $41,723
-650 Reduced 1.43%
44,909 $2.88 Million
Q3 2019

Oct 01, 2019

BUY
$42.77 - $50.71 $607,334 - $720,082
14,200 Added 45.28%
45,559 $2.31 Million
Q2 2019

Jul 18, 2019

SELL
$44.62 - $49.34 $53,544 - $59,208
-1,200 Reduced 3.69%
31,359 $1.42 Million
Q1 2019

Apr 09, 2019

SELL
$45.12 - $53.8 $9,024 - $10,760
-200 Reduced 0.61%
32,559 $1.55 Million
Q4 2018

Feb 15, 2019

BUY
$48.76 - $63.23 $1.6 Million - $2.07 Million
32,759 New
32,759 $1.7 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Campbell Capital Management Inc Portfolio

Follow Campbell Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Campbell Capital Management Inc with notifications on news.